So, hi. Hi, Bino. This is Ankit. So, they didn't specifically mention as to what market it would cover. We are developing products for the global markets, and our site is also designed to service all kinds of markets. So, at some point in time, it will be a combination of both semi-reg markets and reg markets, but let the fine print come, and we'll be able to discuss more specifics then.
See, basically, if you see today, we are a purely injectable company. And as far as the generic product is concerned, we are , by and large, covering most of the opportunities that we can do from our R&D in India. We can't do certain sets of therapeutic categories because of contamination or whatever issues. But outside of that, whatever the addressable market is for us, we are doing it from the R&D capabilities in-house. The way we want to fund the future growth is also to look at outsourcing models and maybe co- development models wherein we can partner with somebody who's more specialized in doing those developments and apportion more budgets and capital investments to that side rather than building it only on the organic R&D side. One, it will speed up the overall process of getting approvals. And second, it will also improve the overall value chain of the products that are going to come onstream for us in the future.